So another test for ovarian cancer?
Sub-B2M prototype achieved 100% sensitivity and specificity. So does Bard1 anticipate this new exosome-based test to be obsolete before reaching the market?
Ann: BARD1 Collaborator Uni of QLD Announces Ovarian Cancer Data, page-12
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
0.005(1.15%) |
Mkt cap ! $49.07M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 44.0¢ | 43.0¢ | $12.55K | 28.78K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 33459 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 8500 | 1 |
View Market Depth
| Last trade - 15.55pm 15/11/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |